Femasys’ (FEMY) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Femasys (NASDAQ:FEMY) in a research report report published on Tuesday morning,Benzinga reports. They currently have a $12.00 price objective on the stock. HC Wainwright also issued estimates for Femasys’ Q4 2024 earnings at ($0.22) EPS, FY2024 earnings at ($0.84) EPS, FY2025 earnings at ($0.42) EPS, FY2026 earnings at ($0.23) EPS, FY2027 earnings at ($0.19) EPS and FY2028 earnings at ($0.04) EPS.

Separately, Chardan Capital lowered their price objective on shares of Femasys from $12.00 to $10.00 and set a “buy” rating on the stock in a research note on Wednesday, August 14th.

Femasys Price Performance

Shares of FEMY stock opened at $0.95 on Tuesday. The firm has a market cap of $21.82 million, a P/E ratio of -1.18 and a beta of -2.83. The firm has a fifty day moving average of $1.16 and a two-hundred day moving average of $1.15. The company has a debt-to-equity ratio of 0.86, a current ratio of 3.94 and a quick ratio of 5.93. Femasys has a 1-year low of $0.73 and a 1-year high of $2.40.

Femasys (NASDAQ:FEMY) last issued its earnings results on Tuesday, November 12th. The company reported ($0.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.04). Femasys had a negative net margin of 1,435.77% and a negative return on equity of 141.49%. The company had revenue of $0.55 million during the quarter, compared to analyst estimates of $0.40 million. As a group, research analysts anticipate that Femasys will post -0.79 earnings per share for the current fiscal year.

Institutional Trading of Femasys

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. CM Management LLC raised its position in Femasys by 6.3% in the 2nd quarter. CM Management LLC now owns 425,000 shares of the company’s stock worth $484,000 after purchasing an additional 25,000 shares during the last quarter. Geode Capital Management LLC increased its stake in Femasys by 9.2% in the third quarter. Geode Capital Management LLC now owns 206,483 shares of the company’s stock valued at $229,000 after purchasing an additional 17,473 shares in the last quarter. XTX Topco Ltd increased its position in shares of Femasys by 123.9% in the 3rd quarter. XTX Topco Ltd now owns 32,535 shares of the company’s stock valued at $36,000 after buying an additional 18,004 shares in the last quarter. Finally, Aljian Capital Management LLC bought a new position in shares of Femasys during the 3rd quarter valued at about $27,000. Institutional investors own 65.27% of the company’s stock.

Femasys Company Profile

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.